Abstract: The present invention relates to the use of PEG-phospholipid molecules to selectively mask surface antigens on erythrocytes, thrombocytes and/or endothelial cells. Blood products treated with PEG-phospholipid molecules can thereby be infused into uncrossmatched or incompatible recipients with reduced risk of antibody binding to the surface antigens and agglutination. Correspondingly, organ transplants treated with PEG-phospholipid molecules can be transplanted into uncrossmatched or incompatible recipients with reduced risk of antibody binding and antibody-mediated rejection.

Abstract: A gangway assembly comprising a gangway for arrangement between two cars of a multi-car vehicle having a first bellows with a frame for connecting to a counter frame of a second bellows of the gangway, a first electrical coupler connected to the frame of the first bellows and a second electrical coupler connected to the counter frame of the second bellows. A first support is connected to the frame of the first bellows. The first electrical coupler is movably mounted on the first support so as to be movable between an advanced position and a retracted position. A second support is fixedly connected to the second bellows counter frame, the second electrical coupler movably mounted on the second support and movable between an advanced position and a retracted position. An advancing mechanism advances the first and second electrical couplers from their respective retracted position to their respective advanced position.

Abstract: In one aspect, the invention provides compositions and methods for preventing, reducing, and/or treating a disease, disorder or condition associated with fibrin-induced activation of the complement system and the associated activation of the coagulation and/or contact systems comprising administering a therapeutic amount of a MASP-2 inhibitory antibody to a subject in need thereof. In some embodiments, the methods of the invention provide anticoagulation and/or antithrombosis and/or antithrombogenesis without affecting hemostasis. In one embodiment of this aspect of the invention, the compositions and methods are useful for treating a subject is suffering from, or at risk of developing, a disease, disorder or condition associated with complement-related inflammation, excessive coagulation or contact system activation initiated by fibrin or activated platelets.

Abstract: A PEG-lipid is produced by mixing a cation-PEG-lipid comprising at least one amino group with a sulfated glycosaminoglycan comprising at least one carbonyl group to form a Schiff base intermediate. A reducing agent is added to the Schiff base intermediate to form a sulfated glycosaminoglycan-PEG-lipid. The sulfated glycosaminoglycan-PEG-lipid can be used to biological tissue against thromboinflammation. Coating of biological tissue with the sulfated glycosaminoglycan-PEG-lipid can be done in a single step process and does not cause any significant cell aggregation.

Abstract: Disclosed is a train coupler connector module for electrically coupling a first rail vehicle to a second rail vehicle, the module including: a fixing block with an inner side able to be mounted on an electrical train coupler; a plurality of contact units arranged side by side in the fixing block, each contact unit having a first end facing the inner side of the fixing block and a second end extending outwards from the fixing block, one of the first and second end being a female contact and the other being a male contact; wherein at least one of the contact units is arranged to be individually removable from the fixing block in a direction outwards from the fixing block.

Abstract: An organ graft is ex vivo treated by ex vivo infusing a solution comprising PEG-phospholipid molecules into a vascular system of the organ graft. The solution comprising PEG-phospholipid molecules is ex vivo incubated in the vascular system to enable coating of at least a portion of the endothelial lining of the vascular system with the PEG-phospholipid molecules while keeping the organ or the part of the organ submerged in an organ preservation solution comprising PEG-phospholipid molecules. Such an ex vivo treatment of organ grafts with PEG-phospholipid protected the organ grafts against thromboinflammation and reduced blood pressure drops that otherwise occurred when reperfusing the organ graft in the recipient.

Abstract: Disclosed is a train coupler connector module for electrically coupling a first rail vehicle to a second rail vehicle, the module including: a fixing block with an inner side able to be mounted on an electrical train coupler; a plurality of contact units arranged side by side in the fixing block, each contact unit having a first end facing the inner side of the fixing block and a second end extending outwards from the fixing block, one of the first and second end being a female contact and the other being a male contact; wherein at least one of the contact units is arranged to be individually removable from the fixing block in a direction outwards from the fixing block.

Abstract: In one aspect, the invention provides compositions and methods for preventing, reducing, and/or treating a disease, disorder or condition associated with fibrin-induced activation of the complement system and the associated activation of the coagulation and/or contact systems comprising administering a therapeutic amount of a MASP-2 inhibitory antibody to a subject in need thereof. In some embodiments, the methods of the invention provide anticoagulation and/or antithrombosis and/or antithrombogenesis without affecting hemostasis. In one embodiment of this aspect of the invention, the compositions and methods are useful for treating a subject is suffering from, or at risk of developing, a disease, disorder or condition associated with complement-related inflammation, excessive coagulation or contact system activation initiated by fibrin or activated platelets.

Abstract: A graft composition intended for transplantation into a human patient comprises an injection solution comprising an isolated therapeutic cell transplant, wherein the therapeutic cell transplant is therapeutic to a human patient, and dextran sulfate, or a pharmaceutically acceptable salt thereof, having an average molecular weight of less than 20,000 Da.

Abstract: Dextran sulfate is used in order to reduce pulmonary uptake of intravenously injected Dextran sulfate is capable of reducing the pulmonary uptake of the intravenously injected cells to the levels obtained for intraarterial injection of the cells but without the accompanying risks and side effects of using intraarterial cell injection. The dextran sulfate can therefore be used in a composition together with tumor infiltrating T-lymphocytes to treat metastatic cancer in a subject.

Abstract: A graft composition intended for transplantation into a patient comprises an injection solution comprising an isolated cell transplant and dextran sulfate, or a pharmaceutically acceptable salt thereof.

Abstract: A graft composition intended for transplantation into a human patient comprises an injection solution comprising an isolated therapeutic cell transplant, wherein the therapeutic cell transplant is therapeutic to a human patient, and dextran sulfate, or a pharmaceutically acceptable salt thereof, having an average molecular weight of less than 20,000 Da.

Abstract: The present invention refers to use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of Instant Blood-Mediated Inflammatory Reaction (IBMIR). In addition, the invention refers to the use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of morphological disruption of cell transplants and graft-rejection of cell transplants caused by IBMIR. The invention may be applied to patients suffering from type I diabetes, in which porcine islets of Langerhans are transplanted in their portal vein. Administration of dextran sulfate according to the invention inhibits and prevents rejection and destruction of the transplanted islets and makes normoglycemia in the patients possible.

Abstract: A method of inhibiting Instant Blood-Mediated Inflammatory Reaction (IBMIR) in a patient, comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof. A method of inhibiting morphological disruption of a transplanted cell transplant in a patient comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof, to a patient. The dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average molecular weight of less than 20,000 Da and an average sulphur content in a range of 10 to 25%, and the inhibition comprises administering said therapeutically effective amount of said dextran sulfate, or said pharmaceutically acceptable salt thereof, resulting in a concentration of said dextran sulfate, or said pharmaceutically acceptable salt thereof, in the blood of said patient of less than 5 mg/ml.

Abstract: A graft composition intended for transplantation into a patient comprises an injection solution comprising an isolated cell transplant and dextran sulfate, or a pharmaceutically acceptable salt thereof.

Abstract: A method of inhibiting Instant Blood-Mediated Inflammatory Reaction (IBMIR) in a patient, comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof. A method of inhibiting morphological disruption of a transplanted cell transplant in a patient comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof, to a patient. The dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average molecular weight of less than 20,000 Da and an average sulphur content in a range of 10 to 25%, and the inhibition comprises administering said therapeutically effective amount of said dextran sulfate, or said pharmaceutically acceptable salt thereof, resulting in a concentration of said dextran sulfate, or said pharmaceutically acceptable salt thereof, in the blood of said patient of less than 5 mg/ml.

Abstract: The present invention refers to use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of Instant Blood-Mediated Inflammatory Reaction (IBMIR). In addition, the invention refers to the use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of morphological disruption of cell transplants and graft-rejection of cell transplants caused by IBMIR. The invention may be applied to patients suffering from type I diabetes, in which porcine islets of Langerhans are transplanted in their portal vein. Administration of dextran sulfate according to the invention inhibits and prevents rejection and destruction of the transplanted islets and makes normoglycemia in the patients possible.

Abstract: Dextran sulfate is used in order to reduce pulmonary uptake of intravenously injected Dextran sulfate is capable of reducing the pulmonary uptake of the intravenously injected cells to the levels obtained for intraarterial injection of the cells but without the accompanying risks and side effects of using intraarterial cell injection. The dextran sulfate can therefore be used in a composition together with tumor infiltrating T-lymphocytes to treat metastatic cancer in a subject.

Abstract: The present invention relates to a particle board comprising a lower and an upper surface layer (9, 11) having a finer fraction of particles (4), and between these surface layers (9, 11) an intermediate layer (13) having a coarser fraction of particles (5). The intermediate layer (13) has a varying density.

Abstract: The present invention relates to a particle board comprising a lower and an upper surface layer (9, 11) having a finer fraction of particles (4), and between these surface layers (9, 11) an intermediate layer (13) having a coarser fraction of particles (5). The intermediate layer (13) has a varying density.